Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Chemoradiation vs Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
NCT01220583Phase 2Active, not recruiting
- Sponsor
- NRG Oncology
- Start
- Jan 2011
- Primary completion
- Dec 2026
- Modality
- Nanoparticles, Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of Cisplatin micelle injection (HA132) in salivary gland cancer (SGC), sponsored by NRG Oncology. Started Jan 2011; status: active, not recruiting.
02
Drugs
Cisplatin micelle injection (HA132)
03
Conditions
salivary gland cancer (SGC)
Beyond the preview
Go deeper on NCT01220583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01220583.